15.043 articles found

Wearable gait analysis for differentiating progressive supranuclear palsy and Parkinson's disease: Clinically interpretable digital biomarkers using machine learning.

Sadeghi M, Barouti E, Lyons KE, Pahwa R, Akinwuntan A, Thompson J, Moon S, Devos H.

Gait Posture · 2026-08-03

DOI: 10.1016/j.gaitpost.2026.110610PMID: 42561739

The acute effects of a single session of intermittent hypoxia on blood biomarker concentrations and sleep parameters in people with Parkinson's disease: A randomized, double-blind, crossover trial.

Faria MH, Kalva-Filho CA, Queiroz VO, Boonstra TW, de Oliveira M, Cursiol JA, Schlenstedt C, Lira FS, Antunes BM, Barbieri FA.

Parkinsonism Relat Disord · 2026-08-03

DOI: 10.1016/j.parkreldis.2026.108922PMID: 42574864

Beyond motor fluctuations: Understanding the clinical correlates of OFF burden in Parkinson's disease.

Ledingham D, Sathyanarayana S, Iredale R, Stewart CB, Foster V, Galley D, Baker MR, Pavese N.

J Parkinsons Dis · 2026-08-02

DOI: 10.1177/1877718x261442857PMID: 42543892

Parkinson's disease-associated psychosis in a Brazilian sample: prevalence and clinical profile

Dourado H, Oliveira I, Lobo C, Procópio G, Lima A, Valença G.

Arquivos de neuro-psiquiatria · 2026-08-01

Positive airway pressure therapy for cognitive enhancement in Parkinson's disease: from statistical signals to clinical practice.

Li W, Ni S.

Sleep · 2026-08-01

DOI: 10.1093/sleep/zsag072PMID: 41810864

Reply to Li and Ni "Positive Airway Pressure Therapy for Cognitive Enhancement in Parkinson's Disease: From Statistical Signals to Clinical Practice".

Lajoie AC, John Kimoff R, Benedetti A, Lafontaine AL, Robinson AR, Létourneau M, Crane J, Scanga A, Noel F, Kaminska M.

Sleep · 2026-08-01

DOI: 10.1093/sleep/zsag148PMID: 42189919

Adaptive deep brain stimulation in Parkinson disease: clinical implementation and outlook.

Florin E, Kühn AA.

Nat Rev Neurol · 2026-08-01

DOI: 10.1038/s41582-026-01239-2PMID: 42373954

Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.

Fernandez HH, Bhatia P, Cloud L, Fietzek UM, Matarazzo M, Molho E, Peckham E, Tarakad A, Combs C, Leoni M, Chang I, Tringali S, Boiser J, Sanchez R, Zadikoff C.

Lancet Neurol · 2026-08-01

DOI: 10.1016/s1474-4422(26)00215-2PMID: 42456682

Discovery of VU6081679, a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor 8 with Efficacy in a Preclinical Model of Parkinson's Disease.

Richardson AE, Ferranti AS, Peng L, Lei X, Han A, Qi A, Rodriguez AL, Chang S, Sant S, Zagol-Ikapitte I, Krishnan S, Thompson Gray A, Wilkinson JC, Kethanapalli SH, Cho HP, Temple KJ, Mi D, Days EL, Bauer JA, Wijesiri NK, Brown BP, Boutaud O, Jones CK, Engers DW, Lindsley CW, Niswender CM, Crocker KE.

ACS Chem Neurosci · 2026-08-01

DOI: 10.1021/acschemneuro.6c00364PMID: 42460925

Decoding Prodromal Lewy Body Disease: Clinical Differences Between Isolated REM Sleep Behavior Disorder and Hyposmia With Dopamine Transporter Deficit.

Banerjee LV, Pasquini J, Henderson R, Pavese N, Anderson KN.

Eur J Neurol · 2026-08-01

DOI: 10.1111/ene.70724PMID: 42560086

The Neuroprotective Potentials of Dual GIP/GLP1-RA (Tirzepatide): From Preclinical Experiments to Clinical Trials: A Scoping Review.

Hawas Y, Abouzid M, Gadelmawla AF, Ewis DK, Khatatbeh A, Negida Y, Negida A.

Brain Behav · 2026-08-01

DOI: 10.1002/brb3.71702PMID: 42608956

Parkinson's disease-associated psychosis in a Brazilian sample: prevalence and clinical profile.

Dourado HN, Oliveira IJW, Lobo CC, Procópio GC, Lima AECP, Valença GT.

Arq Neuropsiquiatr · 2026-08-01

DOI: 10.1055/s-0046-1829035PMID: 42838108